HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and raises the price target from $5 to $8.
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and raises the price target from $5 to $8.